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Introduction
　Magnetic resonance imaging is highly sensitive for detecting breast lesions in general. 
However, the specicity for malignant tissue is relatively low.  The differentiation of malig-
nant from benign breast lesion in contrast-enhanced MRI is determined by tumor morphol-
ogy and kinetic analysis of dynamic studies.  Breast proton magnetic resonance spectroscopy
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Abstract : 1H-MR spectroscopy（MRS）of the breast demonstrated that cho-
line could be detected in breast cancers.  The purpose of this study was to 
evaluate the detectability of the choline peak（Tcho）in breast cancer using 
a 3.0T imager.  A total of 52 female patients who underwent MR imaging 
were evaluated.  Localization methods included the SVS and PRESS, with 
acquisition times of approximately 5 minutes.  Correlations among tumor size, 
histological type, and the presence of Tcho were evaluated.  Of 52 breast 
lesions that were pathologically diagnosed, 50 were malignant［45 invasive 
ductal carcinomas（IDC）, ve ductal carcinomas in situ（DCIS）］and 2 were 
benign.  The presence of Tcho was evaluated in 50 cases.  The average diam-
eter of malignant tumors was 2.2 cm and that of benign tumors was 1.9 cm. 
Tcho was identified in 24 of 48 breast cancers（sensitivity 50％, specificity 
100％）.  There was a signicant difference between the identication in tumors 
according to tumor size.  Tcho was identied in 76.9％ of IDC cases with a 
diameter greater than the voxel size（1.5 cm）, while it was identied in only 
17.6％ of tumors less than 1.5 cm in size.  Tcho was identied in approximately 
77％ of breast cancer tumors overall with a diameter greater than the voxel 
size.  The result was comparable with the detectability at 1.5T, although the 
acquisition times at 3.0T were much shorter than at 1.5T.  The advantages 
at 3.0T include the ability to investigate smaller lesions within a shorter time 
frame.
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（1H-MRS）can demonstrate molecular information of the breast lesions 1-3）.  With the addi-
tion of the tissue metabolism analysis to morphologic and kinetic analysis, the differentiation 
of malignant from benign breast lesions will be improved.  MRS of the breast demonstrates 
the presence of choline（Cho）, which can be detected in breast cancers, where as it usually 
undetected in normal breast tissues2, 5-10）.  Breast MRS is proposed as an adjunct to MRI 
examinations to improve the specificity of detecting malignant breast lesions.  Recently, 
several investigators reported the efcacy of MRS of the breast at 1.5T 6-12）.  However, few 
studies have evaluated MRS of the breast at 3.0T.  This study therefore assessed detection 
of the Cho peak in breast cancer using a 3.0T imager.
Materials and Methods
　The study group comprised 52 female patients aged 37-83 years（mean : 59.7 years）
who underwent diagnostic breast MR imaging from June 2008 to August 2009.  Patients 
undergoing neo-adjuvant chemotherapy for breast cancer were excluded.  All breast lesions 
were histopathologically diagnosed by surgical resection or biopsy.  All MR imaging was 
performed with the patients in the prone position on a 3.0T magnet（MAGNETOM Trio A 
Tim System ; Siemens-Asahi Medical Technologies）.  All examinations were performed bilat-
erally using an open breast array coil.  MRS localization methods used were a single-voxel 
system（SVS）and a PRESS（point-resolved spectroscopy）sequence.  The following acquisi-
tion parameters were used : TR＝2000 msec, TE＝100 msec, average＝150, bandwidth＝
1200 Hz, vector size＝1024, voxel size＝15×15×15 mm, acquisition time＝5 min and 8 sec. 
The selection of the voxel was non-contrast MRI, or contrast-enhanced MRI when neces-
sary.  Contrast material（gadodiamide hydrate, 15 ml ; Omniscan, Daiichi Sankyo, Japan）was 
intravenously injected followed by a saline ush.  Detection of the Cho peak was evaluated 
visually by two radiologists in consensus.  Presence of the Cho peak was correlated with 
tumor size and histological type.
Results
　Of 52 breast lesions, 50 were pathologically diagnosed as malignant tumors, comprising 
45 invasive ductal carcinomas（IDC）and 5 ductal carcinomas in situ（DCIS）.  There were 
2 benign tumors, comprising cyst and normal breast tissue.  In 2 of the 52 cases, the Cho 
peaks were uninterpretable due to signal contamination.  The remaining fty patients were 
evaluated for the presence of the Cho peak.  The average diameter of malignant tumors 
was 2.2 cm and that of benign tumors was 1.9 cm.
　Figs. 1-3 represent MRI and MRS images of patients with IDC with tumors of 2.2×1.0 
cm, 1.2×1.0 cm, and 3.0×2.8 cm in diameter, respectively.  Fig. 1 shows Cho peak detection
（positive）.  Fig. 2 demonstrates the absence of a Cho peak（negative）.  Fig. 3 shows a case 
where it was not possible to interpret the Cho peak due to contamination by noise（uninter-
pretable）.
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　Table 1 details the relationship between the presence of the Cho peak and malignancy of 
the tumors.  Cho peaks were detected in 50.0％ of malignant lesions（24 / 48）, making the 
sensitivity 50.0％.  The specicity was 100％, and the positive predictive value was 50.0％. 
Benign lesions showed no Cho peak（0％）.  Table 2 indicates the relationship between the 
presence of the Cho peak and tumor size.  Cho peaks were detected in 76.9％（20 / 26）of 
tumors with a size greater than the voxel size（≧1.5 cm）, whereas Cho peaks were detected 
in only 17.6％ of the tumors＜1.5 cm in diameter（3 / 17）.  There was a signicant difference 
a
a
b
b
Fig. 1. A 64-year-old patient with an invasive ductal carcinoma（tumor size : 2.2×1.0 cm）.
a : The MRS spectrum is positive for a choline peak.
b : Contrast-enhanced MRI showing a heterogeneous enhanced tumor.
Fig. 2. A 45-year-old patient with an invasive ductal carcinoma（tumor size : 1.2×1.0 cm）.
a : The MRS spectrum is negative for a choline peak.
b : Contrast-enhanced MRI showing a homogeneous enhanced tumor.
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between the detectability of the Cho peak by voxel size（P＜ .01）.  In cases of DCIS, Cho 
peaks were detected in only 20.0％ of cases（1 / 5）.
Discussion
　MRI signals come mainly from protons found in water and lipids.  In MRS, proton 
a b
Fig. 3. A 65-year-old patient with an invasive ductal carcinoma（tumor size : 3.0×2.8 cm）.
a :  The MRS spectrum could not be evaluated due to signal contamination. This 
is an uninterpretable nding.
b : Contrast-enhanced MRI showing a heterogeneous enhanced tumor.
Table 1.　MRS results for the relationship between the detectability of 
the choline peak between malignant and benign tumors
Benign（n＝2） Malignant（n＝48）
Choline positive 0 24
Choline negative 2 24
Positive predictive value（％） 0 50.0
Sensitivity（％） 0 50.0
Specicity（％） 0 0
Table 2.　The relationship between the detectability of the choline 
peak by MRS and tumor size
Tumors size Cho positive Cho negative total ％
Tumor size＞1.5 cm 20 6 26 76.9
Tumor size＜1.5 cm 3 14 17 17.6
DCIS 1 4 5 25.0
Total 24 24 48
Cho, choline peak ; DCIS, ductal carcinoma in situ
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signals originating from hydrogen atoms attached to various metabolites of interest such as 
N-acetyl-aspartate（NAA）（2.02 ppm）, choline（Cho）（3.2 ppm）, creatine（Cr）（3.02 ppm）, 
myo-inositol（mI）（3.57 ppm）, and lactate（Lac）（1.32 ppm）are detectable2, 3）.  Proton mag-
netic resonance spectroscopy（1H-MRS）can obtain molecular information in a non-invasive 
manner.
　Breast 1H-MRS can demonstrate molecular information about the breast lesions.  There 
are increased composite choline metabolites（free choline, phosphocholine, and glycerol 
phosphocholine）in breast cancers, whereas choline is generally undetectable in normal breast 
tissue 2, 4-10）.  Detection of the choline is therefore a useful criteria for differentiating between 
benign lesions and cancer, based on elevated levels of choline compounds being a marker 
of an active tumor.  This is an especially useful method to complement tissue metabolism 
analysis with morphological and kinetic analysis.
Sensitivity and detectability of the choline peak on a 3.0T imager in comparison with a 1.5T 
imager.
　Recently several investigators reported sensitivities of 70-100％ for Cho peak detection 
in breast 1H MRS of malignant lesions at 1.5T（Table 3）.  Yeung et al 6） reported that the 
sensitivity of 1H MRS for detecting the Cho peak was 92％, with a specicity of 83％ in 
all breast lesions（n＝30）.  In their study, the tumors were relatively large（≥1.5 cm）, and 
they did not include tumors smaller than the voxel size 6）.  In other studies, the number of 
tumors with a diameter greater than 1.5 cm was 73％（11 / 15）（Roebuck et al）and 94％
（29 / 31）（Cecil et al）8, 10）.  In these studies, the average（largest dimension）tumor dimen-
sions were 5.1±2.6 cm（Yeung et al）, 2.7±1.0 cm（Cecil et al）, and 2.2±1.0 cm（Roubuck 
et al）, which are all relatively large.  In our study, 35％（17 / 48）of tumors were smaller 
than 1.5 cm, and the average diameter was 2.2 cm.  The reason for the low detectability 
of the Cho peak in our study seems therefore related to the fact that we included many 
tumors smaller than the voxel size.  On the other hand, the sensitivity in the tumors larger 
than the voxel diameter（1.5 cm）was 76.9％ in our study, which is consistent with the prior 
reports using 1.5T imaging.
Table 3.　Results of the MRS study of breast tumors compared with past studies that used a 1.5T imager
Study No. of 
malignant 
lesions
No. of 
benign 
lesions
Sensitivity
（％）
Specicity
（％）
Positive 
predictive 
value（％）
Voxel size
（cm）3
Roebuck et al（1998）8） 10 7 70 86 88 （0.9）—（2.1）
Kvistad et al（1999）7） 11 11 82 82 82 （1.0）—（2.9）
Cecil et al（2001）10） 23 15 83 87 90 （1.0）—（1.5）
Yeung et al（2001）6） 24 6 92 83 97 （1.0）—（4.6）
Tse et al（2003）11） 19 21 89 100 100 not described
Huang et al（2004）12） 18 12 100 67 82 （1.2）—（3.0）
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　Of interest, the acquisition time for 3.0T MRS was about 5 minutes in our study.  On 
the other hand, the acquisition took about 20 minutes in the study by Yeung et al 6）, 
although the acquisition time at 1.5T is always much longer than is needed for 3.0T on the 
same tissue.  Shorter acquisition times is a major advantage of using the 3.0T imager.  If 
we made the voxel size smaller than that used in this study, the acquisition time would be 
slightly longer, however this slightly longer acquisition time would still likely be shorter than 
that of 1.5T MRS.
　About 23％（6 / 26）of the tumors where the diameter was greater than the voxel diame-
ter（≥1.5 cm）did not show a Cho peak.  In 2 cases, the tumors had necrosis.  The necrotic 
area of the tumor was chosen as a region of interest by the MRS spectra.  In one case, the 
position of the tumor was close to the edge of the breast.  Field inhomogeneity and chest 
wall motion on respiration may have been the reason for the lack of a Cho peak in this 
tumor.  Only one of 5 DCIS cases showed a Cho peak on MRS.  The prior reports suggest 
that DCIS may not always demonstrate a Cho peak1, 8, 10, 11, 13）, and our results supports these 
ndings.
　Tumors with a diameter less than the voxel size（＜1.5 cm）showed a low sensitivity
（16％）.  This result was attributed to the fact that small tumors contain normal breast 
adipose tissue around the tumor1）, decreasing the detectable composite choline signal. 
Although we failed to detect a Cho peak in small tumors, advances in 3.0T technology, 
including higher-eld strength MR imagers and advances in the development of coil and 
sequence design may allow MRS investigation of smaller lesions within a short time frame, 
thereby resolving this sensitivity problem.
Conclusion
　MRS demonstrated a Cho peak in 77％ of breast cancers with diameters greater than 
the voxel size.  In spite of the fact that our study included many tumors smaller than those 
examined in prior reports using a 1.5T imager, our results were comparable to these studies. 
In addition, the shorter acquisition time frame is a major advantage of the 3.0T imager. 
We therefore recommend the application of MRS in addition to routine MRI studies, to 
improve the differentiation of malignant from benign breast lesions.
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